Skip to content

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial 1

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Ponesimod was studied in patients with moderate-to-severe psoriasis in a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that evaluated the efficacy, safety and tolerability of 2 dose levels of ponesimod administered during 16 weeks. The most characteristic skin lesions of chronic plaque psoriasis are sharply demarcated erythematous plaques, covered by silvery white scales, which most commonly occur on the elbows, knees, scalp, umbilicus, and lumbar area. About the Phase IIb study with ponesimod in multiple sclerosis 1,2,3. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Request PDF.

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial 2Oral ponesimod in patients with chronic plaque psoriasis: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014 Aug 11; Burcklen M, Stefani M, D’Ambrosio D. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial The Lancet (Lancet) 6 de diciembre 2014 Volumen 384 n 9959 p gina(s) 2036-45. Sator PG, Burcklen M, Stefani M, D’Ambrosio D. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial.

In two randomized trials with a total of 839 patients with mild to moderate plaque psoriasis, calcitriol 3 mcg/g ointment was more effective than vehicle 36. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Secukinumab in plaque psoriasis–results of two phase 3 trials. Several oral and topical small molecules, spanning different therapeutic classes, are proving to be promising treatment options in psoriasis. Key Words: apremilast, baricitinib, dimethyl fumarate, fumaric acid esters, inflammation, JAK inhibitors, Janus kinases, phosphodiesterase 4 inhibitors, ponesimod, psoriasis, ruxolitinib, small molecules, sphingosine 1-phosphate receptor agonists, tofacitinib. For psoriasis, the initial Phase 1 trial was a randomized, doubleblind, placebo-controlled, dose-escalation study examining 5 mg, 10 mg, 20 mg, 30 mg, and 50 mg twice daily (BID) and 60 mg once daily (OD) for 14 days in 59 patients.

Another Oral Agent Demonstrates Clinical Improvement In Chronic Plaque Psoriasis

Prinz JC, Wasfi Y, Li S, et al. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;384(9959):2036-45. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;384(9959):203645. In relapsing remitting MS patients, oral FTY720 shows a superior efficacy when compared to intramuscular interferon- -1a. Actelion is developing ponesimod, an orally available, selective agonist of the sphingosine-1-phosphate (S1P)1 receptor, for the treatment of autoimmune. Phase II development in plaque psoriasis was underway. Jump up Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Secukinumab in plaque psoriasis–results of two phase 3 trials.

Treatment Of Psoriasis

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial.